Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N216951

Product 003
DAPRODUSTAT (JESDUVROQ) TABLET 4MG

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
003	8324208	12/11/2028	DS	DP			02/21/2023
003	8557834	06/22/2027			U-1238		02/21/2023
003	8815884	06/22/2027		DP	U-1238		02/21/2023
003	11117871	03/13/2038	DS	DP	U-3535		02/21/2023
003	11643397	06/22/2027	DS		U-3535		06/07/2023
003	11649217	03/13/2038		DP	U-3535		06/07/2023

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
003	NCE	02/01/2028

 

 

View a list of all patent use codes
View a list of all exclusivity codes